Annovis Bio (NYSE: ANVS), a clinical-stage biotechnology company focused on neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will feature founder, president, and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones. This announcement comes as the company's pivotal Phase 3 Alzheimer's disease (AD) trial is fully enrolled, with top-line data and regulatory submissions expected in 2027.
The webinar will be followed by a live question-and-answer session, providing an opportunity for stakeholders to engage directly with the company's leadership. Annovis also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. Meanwhile, its Parkinson's disease (PD) open-label study is already underway, and discussions are continuing regarding the initiation of a Parkinson's disease dementia program.
Annovis is developing buntanetap, an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients with AD and PD.
The significance of this announcement lies in the potential impact on the neurodegenerative disease landscape. Alzheimer's and Parkinson's diseases affect millions worldwide, and current treatments are largely symptomatic. A disease-modifying therapy like buntanetap could represent a major advancement. The upcoming data from the Phase 3 trial will be critical in determining the drug's efficacy and safety, and the initiation of additional studies signals the company's commitment to thoroughly evaluating the therapy.
The webinar and the milestones discussed are of particular interest to investors, patients, and healthcare professionals. For investors, the progress of the clinical programs and the timeline for data release are key factors in assessing the company's potential. For patients and healthcare providers, the development of a new therapeutic option that targets multiple neurotoxic proteins could offer new hope for better management of these devastating diseases.
The company's efforts extend beyond AD and PD, with plans to explore a Parkinson's disease dementia program. This expansion underscores the potential broad applicability of buntanetap across different neurodegenerative conditions, which share common pathological mechanisms.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company. Its lead drug candidate, buntanetap (formerly posiphen), is being investigated for its ability to inhibit the translation of neurotoxic proteins that are implicated in neurodegeneration. The company's mission is to halt disease progression and improve cognitive and motor functions, addressing the root causes of these conditions.
For more information about Annovis Bio and its programs, visit the company's website at www.annovisbio.com. The full press release for this announcement is available at this link, and the latest news and updates relating to ANVS can be found in the company's newsroom at https://ibn.fm/ANVS.
